description = Create and manage presentations. core = 7.x features[feeds_tamper][] = os_presentation-body-utf8_convert features[feeds_tamper][] = os_presentation ...

TNX-1700, a fusion protein of TFF2 and albumin, is in preclinical development for the treatment of gastric and colorectal cancer in combination with PD-1 blockade. TNX-1700, in-licensed from Columbia ...

A poster presentation often discusses research or an academic project using a poster that can be read and viewed by a large audience. The individual presenter(s) will use their posters to illustrate ...

The Capstone Poster Presentation highlights how final-year engineering students apply their knowledge to real-world challenges. Faculty, industry professionals and the Concordia community are invited ...

The Capstone Poster Presentation highlights how final-year engineering students apply their knowledge to real-world challenges. Faculty, industry professionals and the Concordia community are invited ...

BERKELEY HEIGHTS, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, today ...

The presentations will be made available in the Publications section of the Bicycle Therapeutics website at the beginning of the poster session. Bicycle Therapeutics is headquartered in Cambridge, UK, ...

Copies of the Company’s presentations will be available under the Scientific Presentations tab on the Tonix website at www.tonixpharma.com. About TNX-1700 TNX-1700, a fusion protein of TFF2 and ...

Molecular Partners’ Radio-DARPins are designed as ideal vectors for precise delivery of potent alpha-emitting isotopes to tumor lesions and have the potential to unlock a broad range of tumor targets ...

WALTHAM, Mass., March 20, 2026 (GLOBE NEWSWIRE)-- Sironax, a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunological, ...

KING OF PRUSSIA, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”) , a clinical-stage biotechnology company specializing in molecular glue degraders, today announced that it ...